{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:17:59Z","timestamp":1782782279276,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-02952-x","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T20:02:32Z","timestamp":1707768152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1355-9551","authenticated-orcid":false,"given":"Mariya Asenova","family":"Stoynova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4149","authenticated-orcid":false,"given":"Alexander Dimitrov","family":"Shinkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-5008","authenticated-orcid":false,"given":"Inna Dimitrova","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0416-4091","authenticated-orcid":false,"given":"Inna Angelova","family":"Yankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1894-8433","authenticated-orcid":false,"given":"Roussanka Dimitrova","family":"Kovatcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"2952_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update. J Endocrinol Invest 37:691\u2013700. https:\/\/doi.org\/10.1007\/s40618-014-0097-2","journal-title":"J Endocrinol Invest"},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, risk factors, and prevention of graves\u2019 orbitopathy. Front Endocrinol 11:1\u201310. https:\/\/doi.org\/10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol"},{"key":"2952_CR3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738. https:\/\/doi.org\/10.1056\/NEJMra0905750","journal-title":"N Engl J Med"},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM, EUGOGO \u2020 (2021) The 2021 european group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185:G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Graves\u2019 orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J 2:259\u2013269. https:\/\/doi.org\/10.1159\/000356042","journal-title":"Eur Thyroid J"},{"key":"2952_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000477803","volume":"6","author":"E Sabini","year":"2017","unstructured":"Sabini E, Leo M, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2017) Does graves\u2019 orbitopathy ever disappear answers to an old question. Eur Thyroid J 6:263\u2013270. https:\/\/doi.org\/10.1159\/000477803","journal-title":"Eur Thyroid J"},{"key":"2952_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of Graves\u2019 orbitopathy. Clin Endocrinol 63:395\u2013402. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02352.x","journal-title":"Clin Endocrinol"},{"key":"2952_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM (1998) Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol 82:773\u2013779. https:\/\/doi.org\/10.1136\/bjo.82.7.773","journal-title":"Br J Ophthalmol"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.beem.2011.11.001","volume":"26","author":"WM Wiersinga","year":"2012","unstructured":"Wiersinga WM (2012) Quality of life in Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:359\u2013370. https:\/\/doi.org\/10.1016\/j.beem.2011.11.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/IOP.0000000000001446","volume":"20","author":"THB Lee","year":"2020","unstructured":"Lee THB, Sundar G (2020) Quality of life in thyroid eye disease: a systematic review. Ophthal Plast Reconstr Surg 20:118\u2013126. https:\/\/doi.org\/10.1097\/IOP.0000000000001446","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","volume":"55","author":"AJ Dickinson","year":"2001","unstructured":"Dickinson AJ, Perros P (2001) Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol 55:283\u2013303. https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01349.x","journal-title":"Clin Endocrinol"},{"key":"2952_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","volume":"16","author":"RS Bahn","year":"1987","unstructured":"Bahn RS, Gorman C (1987) Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 16:391\u2013407. https:\/\/doi.org\/10.1016\/S0889-8529(18)30485-7","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2952_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Grave\u2019s ophthalmopathy. Clin Endocrinol 47:9\u201314. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x","journal-title":"Clin Endocrinol"},{"key":"2952_CR14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ophtha.2006.02.060","volume":"113","author":"EA Bradley","year":"2006","unstructured":"Bradley EA, Sloan JA, Novotny PJ, Garrity JA, Woog JJ, West SK (2006) Evaluation of the national eye institute visual function questionnaire in graves\u2019 ophthalmopathy. Ophthalmology 113:1450\u20131454. https:\/\/doi.org\/10.1016\/j.ophtha.2006.02.060","journal-title":"Ophthalmology"},{"key":"2952_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-023-02875-z","author":"MA Stoynova","year":"2023","unstructured":"Stoynova MA, Shinkov AD, Dimitrova ID, Yankova IA, Kovatcheva RD (2023) Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves\u2019 orbitopathy. Int Ophthalmol. https:\/\/doi.org\/10.1007\/s10792-023-02875-z","journal-title":"Int Ophthalmol"},{"key":"2952_CR16","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1007\/s10792-023-02842-8","volume":"43","author":"MA Stoynova","year":"2023","unstructured":"Stoynova MA, Shinkov AD, Novoselski MT, Petrova VV, Dimitrova ID, Yankova IA, Kovatcheva RD (2023) Changes in therapeutic response, ocular manifestations of Graves\u2019 orbitopathy and quality of life during the first year after orbital radiotherapy. Int Ophthalmol 43:4305\u20134314. https:\/\/doi.org\/10.1007\/s10792-023-02842-8","journal-title":"Int Ophthalmol"},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","volume":"152","author":"KA Ponto","year":"2011","unstructured":"Ponto KA, Hommel G, Pitz S, Elflein H, Pfeiffer N, Kahaly GJ (2011) Quality of life in a German Graves\u2019 orbitopathy population. Am J Ophthalmo\u041b 152:483\u2013490. https:\/\/doi.org\/10.1016\/j.ajo.2011.02.018","journal-title":"Am J Ophthalmo\u041b"},{"key":"2952_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/eye.2011.359","volume":"26","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, Lim HT, Lee SJ, Lee SY, Yoon JS (2012) Assessing Graves\u2019 ophthalmopathy-specific quality of life in Korean patients. Eye 26:544\u2013551. https:\/\/doi.org\/10.1038\/eye.2011.359","journal-title":"Eye"},{"key":"2952_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jfma.2013.12.002","volume":"114","author":"IC Lin","year":"2015","unstructured":"Lin IC, Lee CC, Liao SL (2015) Assessing quality of life in Taiwanese patients with Graves\u2019 ophthalmopathy. J Formos Med Assoc 114:1047\u20131054. https:\/\/doi.org\/10.1016\/j.jfma.2013.12.002","journal-title":"J Formos Med Assoc"},{"key":"2952_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","volume":"43","author":"YP Hai","year":"2020","unstructured":"Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ (2020) Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy. J Endocrinol Invest 43:123\u2013137. https:\/\/doi.org\/10.1007\/s40618-019-01116-4","journal-title":"J Endocrinol Invest"},{"key":"2952_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3760\/cma.j.issn.0578-1426.2019.08.006","volume":"58","author":"CY Weng","year":"2019","unstructured":"Weng CY, Li ZF, Hu SD, Luo YS, Feng XT, Zhong Q, Zhang Q, Shen J (2019) Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors. Zhonghua Nei Ke Za Zhi 58:577\u2013583. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2019.08.006","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"2952_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000508071","volume":"9","author":"E Hoppe","year":"2021","unstructured":"Hoppe E, Lee ACH, Hoppe D, Kahaly GJ (2021) Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe graves\u2019 orbitopathy: a prospective trial. Eur Thyroid J 9:313\u2013320. https:\/\/doi.org\/10.1159\/000508071","journal-title":"Eur Thyroid J"},{"key":"2952_CR23","doi-asserted-by":"publisher","first-page":"130","DOI":"10.24839\/1089-4136.JN15.3.130","volume":"15","author":"MA Brennan","year":"2010","unstructured":"Brennan MA, Lalonde CE, Bain JL (2010) Body image perceptions: Do gender differences exist? Psi Chi J Psychol Res 15:130\u2013138. https:\/\/doi.org\/10.24839\/1089-4136.JN15.3.130","journal-title":"Psi Chi J Psychol Res"},{"key":"2952_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fendo.2019.00192","volume":"10","author":"D Villagelin","year":"2019","unstructured":"Villagelin D, Romaldini J, Andrade J, Santos R, Milkos A, Dos Santos Teixeira PF, Ward LS (2019) Evaluation of quality of life in the Brazilian Graves\u2019 disease population: focus on mild and moderate Graves\u2019 orbitopathy patients. Front Endocrinol 10:3\u20138. https:\/\/doi.org\/10.3389\/fendo.2019.00192","journal-title":"Front Endocrinol"},{"key":"2952_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/jc.2016-1220","volume":"101","author":"GJ Kahaly","year":"2016","unstructured":"Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, K\u00f6nig J (2016) Thyroid stimulating antibodies are highly prevalent in hashimoto\u2019s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 101:1998\u20132004. https:\/\/doi.org\/10.1210\/jc.2016-1220","journal-title":"J Clin Endocrinol Metab"},{"key":"2952_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1507\/endocrj.k11e-019","volume":"58","author":"A Yoshihara","year":"2011","unstructured":"Yoshihara A, Yoshimura Noh J, Nakachi A, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y et al (2011) Severe thyroid-associated orbitopathy in Hashimoto\u2019s thyroiditis. Report of 2 cases. Endocr J 58:343\u2013348. https:\/\/doi.org\/10.1507\/endocrj.k11e-019","journal-title":"Endocr J"},{"key":"2952_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12886-018-1018-5","volume":"19","author":"E Cyranska-Chyrek","year":"2019","unstructured":"Cyranska-Chyrek E, Olejarz M, Szczepanek-Parulska ES, Szczepanek-Parulska ES, Poich P, Ruchala M (2019) Severe unilateral orbitopathy in a patient with Hashimoto\u2019s thyroiditis\u2013a case report. BMC Ophthalmol 19:9\u201316. https:\/\/doi.org\/10.1186\/s12886-018-1018-5","journal-title":"BMC Ophthalmol"},{"key":"2952_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1089\/thy.2013.0240","volume":"24","author":"F Menconi","year":"2014","unstructured":"Menconi F, Profilo MA, Leo M, Sisti E, Altea MA, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2014) Spontaneous improvement of untreated mild Graves\u2019 ophthalmopathy: Rundle\u2019s curve revisited. Thyroid 24:60\u201366. https:\/\/doi.org\/10.1089\/thy.2013.0240","journal-title":"Thyroid"},{"key":"2952_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12020-016-1136-x","volume":"57","author":"F Menconi","year":"2017","unstructured":"Menconi F, Leo M, Sabini E, Mautone T, Nardi M, Sainato A, Sellari-Franceschini S, Vitti P, Marcocci C, Marin\u00f2 M (2017) Natural history of Graves\u2019 orbitopathy after treatment. Endocrine 57:226\u2013233. https:\/\/doi.org\/10.1007\/s12020-016-1136-x","journal-title":"Endocrine"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02952-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-02952-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02952-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:50:25Z","timestamp":1741881025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-02952-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-02952-x","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Ethical Committee (approval number 21B\/25.07.2017) and was in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"68"}}